Drug profile · INN
momelotinib
OMJJARA
momelotinib (OMJJARA) is a tyrosine-protein kinase jak1 inhibitor. Associated with GlaxoSmithKline.
EMA: approved TGA: approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — momelotinib
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
momelotinib (OMJJARA) is a tyrosine-protein kinase jak1 inhibitor. Associated with GlaxoSmithKline.
Key facts
INN momelotinib
Brand OMJJARA
Mechanism Tyrosine-protein kinase JAK1 inhibitor
Target Tyrosine-protein kinase JAK1
Originator GlaxoSmithKline
Mechanism of action
Tyrosine-protein kinase JAK1 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is momelotinib?
momelotinib (OMJJARA) is a tyrosine-protein kinase jak1 inhibitor. Associated with GlaxoSmithKline.
What is the brand name for momelotinib?
OMJJARA is a marketed brand name for momelotinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.